News

News
7 April 2025

Genoscience Pharma Grants Exclusive Rights to GNS561 to Genfit for Cancer Treatment Development

MARSEILLE-LILLE, April 07, 2025 – Genoscience Pharma has granted Genfit exclusive rights to develop and…
Read More
News
19 April 2023

Genoscience Pharma has announced a new agreement for research at the Hebrew University of Jerusalem on targeted degradation technology

MARSEILLE-JERUSALEM, April 19, 2023 – Genoscience Pharma a clinical-stage biopharmaceutical company that develops disruptive therapeutics…
Read More
News
1 February 2023

ODD obtained by Genoscience Pharma from FDA to treat HCC

Genoscience Pharma receives FDA Orphan Drug Designation for ezurpimtrostat to treat HepatoCellular Carcinoma (HCC) Ezurpimtrostat…
Read More
News
6 January 2023

Genoscience Pharma announces the start of GNS561’s Phase 2b Clinical Trial

Genoscience Pharma announces launch of phase 2b clinical trial of ezurpimtrostat (GNS561) to treat hepatocarcinoma…
Read More
News
27 October 2022

Prix Galien USA 2022: Genoscience Pharma is nominated in the category “Start-up/Biotech”

Genoscience Pharma has been nominated to the Prix Galien USA 2022 A so excited event…
Read More
News
13 September 2022

Orphan Drug Designation to GNS561 for the treatment of Cholangiocarcinoma to GENFIT

Genoscience Pharma is proud that FDA granted an Orphan Drug Designation to GNS561 (a Genoscience's…
Read More
News
3 March 2022

Liver Cancer, Phase 1b Clinical results publication

Major First in Class Clinical data! Genoscience is proud to announce a new cornerstone of…
Read More
News
17 January 2022

GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition

Since December 2019, SARS-CoV-2 has spread quickly worldwide, leading to more than 280 million confirmed…
Read More
News
17 December 2021

GENOSCIENCE PHARMA out licenses rights of GNS561 in Europe, US and Canada territories in Cholangiocarcinoma

Genoscience is proud to announce the out-licensing of GNS561 in the cholangiocarcinoma in the United…
Read More
News
8 November 2021

GNS561, a clinical-stage PPT1 inhibitor is efficient against Hepatocarcinoma via modulation of lysosomal functions

The Genoscience Pharma's team and its collaborators are happy of this new publication in Autophagy…
Read More